Objective: To identify predictive factors for gastroduodenal bleeding after postoperative radiation therapy in patients with biliary tract cancer. Methods: We identified 186 patients with biliary tract cancer who completed scheduled postoperative radiation therapy from March 2000 to August 2013. To isolate the effects of radiation on gastroduodenal bleeding, patients with pylorus-preserving pancreaticoduodenectomy, pylorusresecting pancreaticoduodenectomy or Whipple surgery (n = 67) were excluded from this analysis. Postoperative radiation therapy was started at a median 5 weeks (range: 4-12 weeks) after surgery with a median dose of 44 Gy (range: 44-54), and chemotherapy was also concurrently administered to 102 patients. Results: The median age of the patients was 59 years (range: 36-76 years). Of the 119 patients, 26 had intrahepatic cholangiocarcinoma, 29 had hilar cholangiocarcinoma, while 64 had extrahepatic tumors (gallbladder cancer, n = 53; proximal bile duct cancer, n = 10; choledochal cyst cancer, n = 1). Of all, 11 patients (9%) developed gastroduodenal bleeding. In univariate analyses, hepatic artery resection and gastroduodenal wall thickening on postoperative radiation therapy simulation computed tomography were statistically significant factors for gastroduodenal bleeding. Multivariate analysis by a logistic regression model using those two variables revealed that both parameters were independent predictors for gastroduodenal bleeding. Conclusions: Concomitant hepatic artery resection and presence of gastroduodenal wall thickening on postoperative radiation therapy simulation computed tomography were predictive factors for gastroduodenal bleeding after postoperative radiation therapy in biliary tract cancer. In such cases, patients should be informed of the high risk of gastroduodenal bleeding, and should be closely observed during and after postoperative radiation therapy.
Introduction
Biliary tract cancer (BTC) is a rare tumor accounting for~4% of gastrointestinal cancers (1) . Resection has been the only potentially curative option, but locoregional recurrence following surgery may occur in patients with BTC (1) (2) (3) . Improvement in overall survival (OS) with postoperative radiation therapy (PORT) with or without chemotherapy has been reported in a recent meta-analysis of BTCs although there is no randomized phase III clinical trial yet (2) . Additionally, several retrospective studies have suggested that PORT may improve local control and survival for extrahepatic cholangiocarcinoma (4-7). However, normal organ toxicities often limit the amount of radiation that can be delivered to achieve a therapeutic dose (8) . Among other complications, gastroduodenal (GD) bleeding is a major clinical issue while few studies on incidence after PORT in BTC have been found in the literature. We can only postulate the incidence of GD bleeding from studies of PORT in hilar cholangiocarcinoma, whose incidence was 9-17% after PORT in hilar cholangiocarcinoma (3, 9) . Most bleeding stops spontaneously; however, it is potentially life-threatening in some patients (8) . Little is yet known concerning incidence and predictive factors for GD bleeding after PORT in BTC. The aim of this study was to determine predictive factors for GD bleeding after PORT for BTC following surgical resection.
Materials and methods

Patients and treatment
This study was performed in accordance with the guidelines of the Institutional Review Board of the Samsung Medical Center (IRB No. 2014-07-143). The present study included 194 patients with BTC who received curative surgery and scheduled PORT at Samsung Medical Center between March 2000 and August 2013. Cases involving distant metastasis (DM) (n = 3), history of previous GD ulcer (n = 3), and history of previous radiotherapy (RT) (n = 2) were excluded. To isolate the effects of radiation on GD bleeding, patients with pylorus-preserving pancreaticoduodenectomy, pylorusresecting pancreaticoduodenectomy, or Whipple surgery (n = 67) were excluded from the analysis. Remaining 119 patients of BTC who did not undergo duodenectomy is subset of our analysis to evaluate effects of factors to duodenum.
All patients received 3-dimensional conformal RT so as to avoid delivery of high doses to the liver, small bowel, and kidneys as much as possible. Patents were treated using two-(anterior-posterior/ posterior-anterior [AP/PA]) or three-field technique (AP/PA or right anterior oblique/left posterior oblique [RAO/LPO] with right or left lateral). The clinical target volume was determined with a 1-1.5 cm radial margin around the tumor bed and regional lymphatics (i.e. porta hepatis, pericholedochal, celiac, pancreaticoduodenal). An extra margin of 1-1.5 cm in the craniocaudal direction was added to account for respiratory organ motion, from 3 cm superior to the celiac axis to 3 cm inferior to the left renal vein. PORT was chiefly delivered with 10 MV photons. The total radiation dose was 44 Gy, with a boost dose of 10 Gy if the resection margin was positive or close (≤1 mm).
Preoperative clinical characteristics (age, comorbidities, primary tumor status), intraoperative variables including type of surgery (extended hemihepatectomy vs. others including hemihepatectomy, bisectionectomy, sectionectomy, cholecystectomy, wedge resection and mass excision) and extent of surgery (concomitant caudate lobe resection, extrahepatic bile duct resection, lymphadenectomy and concomitant resection of portal vein, hepatic artery or inferior vena cava) and postoperative variables (RT dose, concurrent chemotherapy) were analyzed and correlated with the development of GD bleeding. Furthermore, we analyzed the impact on GD bleeding of GD wall thickening on simulation computed tomography (CT).
Review of GD wall thickening on simulation CT
CT scans for PORT planning (simulation CT) were performed for each patient after the intravenous administration of contrast material. All patients were asked to fast for 8 h before the simulation CT and to perform shallow respiration to minimize the motion. A set of transverse images was collected at 5 mm-thick intervals, and the images were transferred to a Pinnacle treatment-planning station (ADAC Laboratories, Milpitas, CA, USA). We reviewed the simulation CT, which was taken at a median 4 weeks after operation, and assessed GD wall thickening (as a potential predictor of GD toxicity). GD wall thickening was defined as the presence of target sign ( Fig. 1) (10) , or of wall thickening ≥5 mm in the duodenum (11), or ≥12 mm in the gastric antrum on simulation CT (12) . Target sign was defined as a bowel wall demonstrating three layers consisting of a contrast-enhanced inner layer and an outer layer, between which is a layer of decreased attenuation on CT (10).
Evaluation of GD bleeding episodes
GD bleeding related to treatment was defined as development of GD bleeding within the radiation port that was not caused by other medical conditions or direct invasion of tumor. The grade of GD bleeding was determined using the National Cancer Institute Common Terminology Criteria of Adverse Events, version 4.0. Grade 3 or greater GD bleeding was detected by endoscopic exploration performed on patients with any sign of upper abdominal pain or discomfort, with or without anemia or bloody stool. The maximal grade and the interval from the start of RT to the occurrence of GD bleeding were noted for analysis. Patients were grouped according to the presence of GD bleeding (absent vs. present). Presence of GD bleeding was defined as grade 2 or greater GD bleeding. Figure 1 . Target sign, defined as bowel wall, exhibits three layers consisting of a contrast-enhanced inner layer and outer layer, between which is a layer of decreased attenuation on CT.
Statistics
The chi-square test, Fisher's exact test, or Student's t-test were used for intergroup comparisons. The Cox proportional hazards regression model was used for multivariate analysis. The actuarial rates of GD bleeding were measured from the day of surgery and were calculated using the Kaplan-Meier method and compared by the log-rank test. A P value < 0.05 was considered to indicate statistical significance. Statistical analysis was performed using PASW 21.0 software for Windows (SPSS, Chicago, IL).
Results
Patients and treatments
The median follow-up time of all patients was 19 months (range: 3-162 months). Overall, 26 patients (22%) had intrahepatic cholangiocarcinoma, 29 patients (24%) had hilar cholangiocarcinoma and 64 patients (54%) had extrahepatic tumors (gallbladder cancer, n = 53; proximal bile duct cancer, n = 10; choledochal cyst cancer, n = 1). All patients had surgery with curative intent; 56 (47%) patients had hemihepatectomy (extended hemihepatectomy, n = 28; hemihepatectomy, n = 28), 32 (27%) patients had bisectionectomy or sectionectomy, 27 (23%) patients had cholecystectomy, three (3%) patients had wedge resection and one (1%) patients had mass excision. Lymphadenectomy was performed for 91 patients (76%), and lymph node sampling was performed for 15 patients (13%). Concomitant portal vein, hepatic artery, or inferior vena cava resection was performed for 11, 6 and 1 patient, respectively.
PORT was initiated at a median 5 weeks (range: 4-12 weeks) after surgery. Patients received one fraction per day, 5 days per week. The median radiation dose was 44 Gy (range: 44-54 Gy). The median duration of PORT was 5 weeks (range: 5-8 weeks). Chemotherapy was concurrently administered to 102 patients (86%), with 2 patients receiving gemcitabine-based treatment and 100 receiving 5-fluorouracil (5-FU) (n = 62) or capecitabine (n = 38) treatment. The characteristics of the patients at the time of PORT are summarized in Table 1 . In total, GD bleeding was found in 11 patients (9%). There were no significant differences in characteristics between patients with and those without GD bleeding.
Of total, 35 patients (29%) recurred during follow-up period. Of all, 25 patients (21%) had distant recurrence and 15 patients (13%) had local recurrence. Liver metastasis was most common site of failure. Five patients of 11 who had GD bleeding had recurrence, three patients of these received salvage chemotherapy for distant recurrence and one patient had local recurrence which caused portal hypertensive gastropathy. However, there was no significant difference on GD bleeding between patients with and those without recurrence (P = 0.297). Gastroduodenal wall thickening and gastroduodenal bleeding GD wall thickening on simulation CT was observed in 36 patients (30%). Target sign was observed in nine patients. A total of 29 patients had duodenal wall thickening measuring from 5 to 14 mm (median 6 mm), and five patients had antral wall thickening measuring from 12 to 18 mm (median 13 mm). The characteristics of 11 patients with GD bleeding after PORT are summarized in Table 2 . The median time to the development of GD bleeding was 12 months (range, 4-51 months). The actuarial 1-and 2-year rates of GD bleeding were 6 and 9%, respectively. The bleeding foci were located on the duodenum in 8 patients, and the gastric antrum in two patients. All patients had received full dose to part of medial or posterior wall of duodenal bulb or gastric antrum although we tried maximal effort to exclude gastro-duodenum. However, it is difficult to correlate endoscopic findings with simulation CT images. One patient was treated with medication in the outpatient clinic, and 10 patients were hospitalized to control GD bleeding. Bleeding was treated with endoscopic hemostasis, or medical treatments including transfusion or intravenous proton pump inhibitors. One patient died during endoscopic hemostasis.
Predictors of gastroduodenal bleeding
The results of a univariate analysis evaluating the association between the clinical parameters and GD bleeding are summarized in Table 3 . On univariate analysis, concomitant hepatic artery resection and GD wall thickening on simulation CT were significant predictive parameters of GD bleeding (Fig. 2) . Type of surgery (extended hemihepatectomy vs. others), radiation dose, and use of concurrent chemotherapy were not predictive parameters for GD bleeding. On multivariate analysis, concomitant hepatic artery resection and GD wall thickening on simulation CT were significant predictive parameters of GD bleeding (Table 4 ). There was no association between hepatic artery resection and GD wall thickening on simulation CT. Discussion PORT, with or without chemotherapy, has been considered to be an effective treatment modality in BTC after curative resection which needs perform of randomized phase III clinical trial (2, 4) . However, the concern remains of multimodality treatment-related toxicity. Bleeding of the stomach and duodenum are among the important dose-limiting toxicities in RT for the treatment of upper gastrointestinal cancer (13) (14) (15) . The prevalence, patterns, and predictors for radiation-induced GD bleeding are important considerations for physicians. Most bleeding stops spontaneously; however, it is potentially life-threatening in some patients (8) . There have been few reports evaluating the predictive factors of GD bleeding after PORT in BTC.
The overall incidence of GD bleeding was 9-17% after PORT in BTC (3,9). Gerhards et al. reported that 17% of hilar cholangiocarcinoma treated with PORT experienced GD bleeding (9). Cheng et al. reported that 9% of hilar cholangiocarcinoma experienced GD bleeding after PORT (3) . In this study, the overall incidence of GD bleeding was 9%, despite the administration of an irradiation dose considered to be safe with respect to risk of GD bleeding. All GD bleeding was within the irradiation field and duodenal bulb was most common site followed by gastric antrum. Most of GD bleedings were occurred within 14 months. But, two patients experienced GD bleeding at 51 months and 40 months, which were far late as considered radiation-induced bleeding. It is possible that various mechanisms as defective drainage or tumor recurrence have been affected (16) . One patient had portal hypertensive gastropathy due to local recurrence and it might influence to GD bleeding. However, we failed to show any correlation between recurrence or salvage treatments and risk of GD bleeding. The analysis of number of risk factors for GD bleeding related to surgery itself, including vascular damage or bowel wall thickening, is required.
In the present study, concomitant hepatic artery resection was performed on 5% of all patients, and was found to be a predictor of GD bleeding. Associations between hepatic artery damage and GD toxicity have been suggested to occur in various therapeutic procedures. It has been reported that right hepatic artery injury is associated with a higher incidence of postoperative abscess, bleeding, hemobilia, and hepatic ischemia (17, 18) . It has also been reported in studies on hepatic artery infusion chemotherapy that mucosal irritation is induced by hepatic artery damage (13, 19) . Disruption of the hepatic arterial blood supply has been demonstrated to influence the pathogenesis of biliary leaks and stenosis (20) . There are reports that patients with combined bile duct and right hepatic artery injuries experienced various gastrointestinal complications, including destructive cholangitis, liver infarction, and secondary biliary cirrhosis (20) . GD wall thickening was observed in 30% of patients who received curative surgery in the present study. There have been no reports thus far regarding the frequency and pattern of CT findings of GD wall thickening in patients with biliary tract cancer, to our knowledge. Different criteria have been used to define bowel wall thickening in previous literature (11, 12, 21) . In our study, we defined it based on the thickness of the duodenal or antral wall (11, 12) , or the presence of target sign representing bowel wall thickening (10, 22) . However, grading of GD wall thickening may differ among physicians. Moreover, it is difficult to distinguish the GD wall from GD content because the volume of the stomach and duodenum vary with food-filling status and respiratory motion (23) . The timing of evaluation of the grading of GD wall thickening is also important. Minor injuries to structures during surgery can induce postoperative bowel edema or inflammation (16) . In our analysis, we used simulation CT for grading of GD wall thickening to exclude acute effects of surgery which was taken at a median 4 weeks after surgery.
GD wall thickening on simulation CT was a predictor of GD bleeding in the present study. The most common causes of small bowel wall thickening are infectious and inflammatory conditions, and it is also associated with other conditions, such as use of cytoreductive agents, surgery, or radiation (24) . Gastrointestinal wall thickening is also more frequently seen in patients with cirrhosis than in a control group (64 vs. 7%, P < 0.005) (21) . It is known to be generally caused by edema (21) . Type of surgery itself was not a predictor of GD bleeding in our study. However, GD wall thickening, which might be caused by edema or inflammatory conditions after surgery, was a predictive factor for GD bleeding (16) .
By its nature, our study was subject to several limitations. First, heterogeneity of patient characteristics, tumor site, and stage, are 
Conclusion
This is the first study to report predictive factors for the development of GD bleeding after PORT in BTC. Our findings indicate that concomitant hepatic artery resection and GD wall thickening on simulation CT correlate with GD bleeding. In these cases, we need to inform patients of the high risk of GD bleeding, and should closely observe them during and after PORT. The evaluation of these factors should be considered in the selection of patient treatment modalities, and may be helpful in choosing novel radiation techniques, such as intensity-modulated RT. The results of the present study depend on retrospectively collected patient records from a relatively small population. Any conclusions should be confirmed in a larger prospective study.
